Company Profile

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE777.251.85 (+0.24 % )
PREV CLOSE (Rs.) 775.40
OPEN PRICE (Rs.) 775.50
BID PRICE (QTY) 776.00 (188 )
OFFER PRICE (QTY) 776.60 (365 )
VOLUME 17921
TODAY'S LOW / HIGH (Rs.)771.00 780.00
52 WK LOW / HIGH (Rs.)527.05 830
NSE773.10 -2.75 (-0.35 % )
PREV CLOSE(Rs.) 775.85
OPEN PRICE (Rs.) 779.95
BID PRICE (QTY) 773.10 (1340 )
OFFER PRICE (QTY) 773.50 (66 )
VOLUME 377506
TODAY'S LOW / HIGH(Rs.) 770.50 779.95
52 WK LOW / HIGH (Rs.)527 830.45

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.32
TTM EPS (Rs.) 23.52
P/E Ratio 32.88
Book Value (Rs.) 188.62
Face Value (Rs.) 1
MCap (Rs. in Mn) 453053.06
Price/Earning (TTM) 25.55
Price/Sales (TTM) 4.10
Price/Book (MRQ) 4.10
PAT Margin (%) 17.59
ROCE (%) 19.02
Incorporation Year : 1986

Management Info :

K Ragunathan - Chairman N Govindarajan - Managing Director

Registered Office :

Address : Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone : +91-040-66725000

Website : www.aurobindo.com

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
02Mar03-02-2019$Aurobindo Pharma’s arm completes acquisition of marketed portfolio from Spectrum Pharma Aurobindo Pharma’s arm com

Acrotech Biopharma LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is a wholly owned subsidiary of Aurobindo Pharma, has completed acquisition of seven marketed oncology injectable products, intellectual property and commercial infrastructure from Spectrum Pharmaceuticals Inc., a US based global branded oncology company. The acquisition has been completed on March 1, 2019.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Acrotech Biopharma LLC, a wholly owned subsidiary of Aurobindo..
02Mar03-02-2019$Aurobindo Pharma informs about acquisition Aurobindo Pharma informs abo

With reference to its letter dated January 17, 2019 informing about entering into a definitive agreement to acquire seven marketed oncology injectable products, intellectual property and commercial infrastructure from Spectrum Pharmaceuticals Inc., (NASDAQ:SPPI), a US based global branded oncology company by Acrotech Biopharma LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is a wholly owned subsidiary of the Company. In this regard, Aurobindo Pharma has informed that the aforesaid acquisition has been completed on March 1, 2019.

The above information is a part of company’s filings submitted to BSE.

 


With reference to its letter dated January 17, 2019 informing a..
01Mar03-01-2019$Aurobindo Pharma informs about clarification Aurobindo Pharma informs abo

Aurobindo Pharma has informed about clarification on news item appeared in business standard on February 27, 2019 titled ‘Lacunae in Aurobindo Pharma's Medak facility in Andhra, says FDA report’ and in Financial Express on February 28, 2019 titled ‘Lacunae in Aurobindo Pharma's facility: FDA report’.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma has informed about clarification on news item..
11Feb02-11-2019$Aurobindo Pharma completes acquisition of Apotex’s Businesses in five European countries Aurobindo Pharma completes a

Aurobindo Pharma has closed the acquisition of Apotex’s commercial operations and certain supporting infrastructure in five European countries. The binding agreement to acquire five of Apotex' European businesses, including infrastructure, personnel, products, certain established trademarks, marketing authorizations and dossier license rights in Poland, the Czech Republic, the Netherlands (including the manufacturing facility in Leiden), Spain and Belgium was announced on July 14, 2018.

Jefferies International acted as sole financial advisor and Herbert Smith Freehills LLP acted as legal counsel to Aurobindo. Ernst & Young, India provided financial due diligence services.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma has closed the acquisition of Apotex’s comme..
11Feb02-11-2019$Aurobindo Pharma informs about press release Aurobindo Pharma informs abo

Aurobindo Pharma has informed about submission of a copy of the Press Release that is being issued by the Company in connection with Completion of the Acquisition of Apotex’ Businesses in Poland, Czech Republic, the Netherlands, Spain and Belgium.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma has informed about submission of a copy of the..
Financials More
Rs. in Millions
QTR Dec 18 ANNUAL 18
Net Profit4635.118127.7
Gross Profit 5846.8 23429.4
Operating Profit 7351.927506.6
Net Sales 32481103031.5
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Piramal Enterprises (BSE)
 2619.65 (1.77%)
M.Cap ( in Cr)
48047.83
Valiant Organics (BSE)
 1575.00 (1.94%)
M.Cap ( in Cr)
923.64
Sanofi India (BSE)
 5590.00 (0.53%)
M.Cap ( in Cr)
12875.61
Torrent Pharma (BSE)
 1883.00 (1.05%)
M.Cap ( in Cr)
31929.69
Glenmark Pharma (BSE)
 647.15 (1.71%)
M.Cap ( in Cr)
18129.30
Shareholding Pattern More
PROMOTERS 51.87 %
MUTUAL FUNDS/UTI 14.13 %
NON-INSTITUTION 13.62 %
FI/BANKS/INSURANCE 0.31 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes

Open A

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested